تاریخچه درآمد، سود و جریان نقد از صورتهای مالی رسمی.
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
نمودارهای تعاملی و صورتهای مالی کامل ← مدل ارزشگذاری (DCF) ←
| صورت سود و زیان | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| مجموع درآمد | $800M | $616M | $329M | $234M | $3M | $7M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | — | — | — | — | — |
| سود ناخالص | $658M | $516M | $291M | $220M | $3M | $6M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | — | — | — | — | — |
| حاشیه سود ناخالص % | 82.2% | 83.7% | 88.3% | 94.0% | 90.5% | 88.2% | 100.0% | 100.0% | 42.1% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — | — | — | — |
| سود عملیاتی (EBIT) | $136M | $123M | $42M | $21M | ($218M) | ($345M) | ($274M) | ($169M) | ($174M) | ($119M) | ($79M) | ($63M) | ($56M) | ($23M) | ($27M) | ($1M) | ($2M) | ($2M) | ($4M) | ($12M) | ($10M) |
| حاشیه سود عملیاتی % | 17.0% | 20.0% | 12.7% | 8.8% | -7839.0% | -5154.3% | -179996.0% | -111220.4% | -114736.8% | -77904.6% | -51823.5% | -41461.9% | -36567.0% | -15071.4% | -141196.5% | — | — | — | — | — | — |
| سود خالص | $442M | $447M | $23M | $13M | ($224M) | ($348M) | ($279M) | ($173M) | ($173M) | ($118M) | ($78M) | ($63M) | ($56M) | ($20M) | ($18M) | ($1M) | $1M | ($3M) | ($4M) | ($12M) | ($10M) |
| حاشیه سود خالص % | 55.2% | 72.6% | 7.1% | 5.4% | -8036.3% | -5204.1% | -183803.3% | -113730.9% | -114132.9% | -77749.9% | -51353.4% | -41310.0% | -36606.5% | -13438.8% | -94879.9% | — | — | — | — | — | — |
| EBITDA | — | $134M | $50M | $26M | ($213M) | ($342M) | ($273M) | ($167M) | ($173M) | ($119M) | ($79M) | ($63M) | ($56M) | ($20M) | ($25M) | ($1M) | $2M | ($2M) | ($4M) | ($12M) | ($10M) |
| سود هر سهم (EPS) | $2.74 | $2.77 | $0.15 | $0.09 | $-1.65 | $-2.63 | $-2.42 | $-1.96 | $-2.30 | $-1.91 | $-1.60 | $-1.38 | $-1.64 | $-0.81 | $-1.38 | $-0.44 | $15.68 | $-111.24 | $-170.00 | $-497.55 | $-453.62 |
| سهام منتشرشده (میلیون) | — | 161M | 160M | 149M | 135M | 132M | 115M | 88M | 75M | 62M | 49M | 46M | 34M | 25M | 13M | 2M | 0M | 0M | 0M | 0M | 0M |
منبع: گزارشهای عمومی شرکت (SEC). پیش از اتکا به هر رقم، آن را در SEC EDGAR بررسی کنید.
ترازنامهها، جریانهای نقدی، دادههای فصلی و نسبتهای مالی کامل در نمایشگر تعاملی TGTX در دسترس است. /companies/us/TGTX
اطلاعات این وبسایت صرفاً برای اهداف آموزشی و اطلاعرسانی است و توصیه سرمایهگذاری نیست. هیچ هدف قیمتی یا توصیهای منتشر نمیشود.
About TickerBase · Data methodology & sources · Privacy · Terms